Azora Therapeutics, Inc. has made a significant update in its ownership structure, as disclosed in a recent SEC filing. The filing, dated November 10, 2026, reveals that Paul J. Hastings is now a reporting owner for the company. This change is important as it reflects the company's ongoing adjustments in compliance with regulatory requirements.

Background

Azora Therapeutics, Inc. is a Delaware-based company primarily engaged in the pharmaceutical preparations sector, as categorized under SIC 2834. The company trades on the Nasdaq under the ticker symbol AZR. Azora Therapeutics has been active in the market, with recent filings indicating a focus on transparency and compliance.

What the Filing Says

The SEC filing indicates that Paul J. Hastings, identified as a director, is now a reporting owner. The document states, "Exhibit 24, Power of Attorney, is attached," which suggests that Hastings has granted authority to others to act on his behalf regarding SEC filings.

Impact

This ownership update may affect investors and stakeholders in Azora Therapeutics, as changes in reporting ownership can influence perceptions of corporate governance and transparency. The filing reflects the company's commitment to adhering to SEC regulations, which is crucial for maintaining investor confidence.

What's Next

The filing does not say what happens next.